<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808860</url>
  </required_header>
  <id_info>
    <org_study_id>Diabetes II-Study 2</org_study_id>
    <secondary_id>Study 2</secondary_id>
    <nct_id>NCT00808860</nct_id>
  </id_info>
  <brief_title>Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients</brief_title>
  <official_title>Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanoi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish International Development Cooperation Agency (SIDA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hanoi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aimed at investigating effect of Gynostemma pentapyllum (GP) extract,
      administered as a &quot;tea&quot;, as add-on therapy with Sulfonylurea (SU) in drug-naive patients with
      newly diagnosed type 2 diabetes. After screening, all patients received gliclazide MR 30mg
      and instruction regarding diet and physical exercise for 12 weeks. After 4 weeks treated with
      gliclazide MR 30mg, the patients was randomized to additional GP tea or placebo tea, 3 g
      twice daily during 8 weeks. Oral glucose tolerance tests were performed at baseline, after 4
      and 12 weeks. Blood tests were taken with the purpose to monitor lipids, kidney and liver
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Vietnam, herbal extracts have been used as a long-standing tradition to treat diabetic
      patients, but effects of these extracts have not been studied adequately. Based on previous
      results in experimental animal, the investigators have selected the plant Gynostemma
      pentapyllum (GP), which grows in the mountain region of Northern Vietnam. GP extract had a
      hypoglycemic effect on mice and rat. In addition, GP has been shown to reduce both
      hyperglycemia and hyperlipidemia in diabetic Zucker fatty rats.The present study aimed at
      investigating effect of Gynostemma pentapyllum (GP) extract, administered as a &quot;tea&quot;, as
      add-on therapy with Sulfonylurea (SU) in drug-naive patients with newly diagnosed type 2
      diabetes.In addition to monitoring effects plasma glucose regulation, the investigators also
      studied possible effects on plasma lipids, kidney and liver function as well as body weight
      and blood pressure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting plasma glucose</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1C (glycosylated hemoglobin)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver enzymes (AST, ALT)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function (S-creatinine, S-BUN)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma lipids (TG, Cholesterol, HDL-, LDL-)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight (BMI, hip-weight ratio)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gliclazide + Placebo tea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gliclazide + Gynostemma pentaphyllum tea</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GP group</intervention_name>
    <description>Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally</description>
    <arm_group_label>GP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, drug-naive patients with type 2 diabetes

          -  Fasting plasma glucose (FPG)9.0-14.0 mmol/L

          -  HbA1C 9-13%

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Liver failure

          -  Kidney failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claes-Goran Ostenson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Gerontology, HMU</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Huyen VT, Phan DV, Thang P, Hoa NK, Ostenson CG. Antidiabetic effect of Gynostemma pentaphyllum tea in randomly assigned type 2 diabetic patients. Horm Metab Res. 2010 May;42(5):353-7. doi: 10.1055/s-0030-1248298. Epub 2010 Mar 8.</citation>
    <PMID>20213586</PMID>
  </reference>
  <reference>
    <citation>Hoa NK, Phan DV, Thuan ND, Ostenson CG. Screening of the hypoglycemic effect of eight Vietnamese herbal drugs. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):165-9. doi: 10.1358/mf.2009.31.3.1362514.</citation>
    <PMID>19536359</PMID>
  </reference>
  <results_reference>
    <citation>Hoa NK, Norberg A, Sillard R, Van Phan D, Thuan ND, Dzung DT, Jörnvall H, Ostenson CG. The possible mechanisms by which phanoside stimulates insulin secretion from rat islets. J Endocrinol. 2007 Feb;192(2):389-94.</citation>
    <PMID>17283239</PMID>
  </results_reference>
  <results_reference>
    <citation>Norberg A, Hoa NK, Liepinsh E, Van Phan D, Thuan ND, Jörnvall H, Sillard R, Ostenson CG. A novel insulin-releasing substance, phanoside, from the plant Gynostemma pentaphyllum. J Biol Chem. 2004 Oct 1;279(40):41361-7. Epub 2004 Jun 25.</citation>
    <PMID>15220351</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2008</study_first_posted>
  <last_update_submitted>December 3, 2010</last_update_submitted>
  <last_update_submitted_qc>December 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2010</last_update_posted>
  <keyword>Herbal medicine</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Gynostemma pentaphyllum Tea</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>add-on</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gliclazide</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

